Cargando…
An ETV6-ABL1 fusion in a patient with chronic myeloproliferative neoplasm: Initial response to Imatinib followed by rapid transformation into ALL
We report the case of a 26 year-old patient presenting with a persistent leukocytosis and CML-like marrow but no evidence of a BCR/ABL1 fusion. Molecular cytogenetics revealed that a portion of the ETV6 locus was inserted into the ABL1 locus. An ETV6/ABL1 fusion transcript could subsequently be conf...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5078675/ https://www.ncbi.nlm.nih.gov/pubmed/27812500 http://dx.doi.org/10.1016/j.lrr.2016.09.002 |
_version_ | 1782462429472489472 |
---|---|
author | Kakadia, Purvi M. Schmidmaier, Ralf Völkl, Andreas Schneider, Irene Huk, Natalia Schneider, Stephanie Panzner, Gerda Neidel, Ulrike Fritz, Barbara Spiekermann, Karsten Bohlander, Stefan K. |
author_facet | Kakadia, Purvi M. Schmidmaier, Ralf Völkl, Andreas Schneider, Irene Huk, Natalia Schneider, Stephanie Panzner, Gerda Neidel, Ulrike Fritz, Barbara Spiekermann, Karsten Bohlander, Stefan K. |
author_sort | Kakadia, Purvi M. |
collection | PubMed |
description | We report the case of a 26 year-old patient presenting with a persistent leukocytosis and CML-like marrow but no evidence of a BCR/ABL1 fusion. Molecular cytogenetics revealed that a portion of the ETV6 locus was inserted into the ABL1 locus. An ETV6/ABL1 fusion transcript could subsequently be confirmed. The patient was started on imatinib and went into complete cytomorphological remission. QRT-PCR measurements showed a 4 log reduction of the ETV6/ABL1 fusion. 15 months later, the disease transformed into ALL and the patient expired. Thus, an ETV6/ABL1 fusion positive MPN has the potential to transform very rapidly into ALL. |
format | Online Article Text |
id | pubmed-5078675 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-50786752016-11-03 An ETV6-ABL1 fusion in a patient with chronic myeloproliferative neoplasm: Initial response to Imatinib followed by rapid transformation into ALL Kakadia, Purvi M. Schmidmaier, Ralf Völkl, Andreas Schneider, Irene Huk, Natalia Schneider, Stephanie Panzner, Gerda Neidel, Ulrike Fritz, Barbara Spiekermann, Karsten Bohlander, Stefan K. Leuk Res Rep Article We report the case of a 26 year-old patient presenting with a persistent leukocytosis and CML-like marrow but no evidence of a BCR/ABL1 fusion. Molecular cytogenetics revealed that a portion of the ETV6 locus was inserted into the ABL1 locus. An ETV6/ABL1 fusion transcript could subsequently be confirmed. The patient was started on imatinib and went into complete cytomorphological remission. QRT-PCR measurements showed a 4 log reduction of the ETV6/ABL1 fusion. 15 months later, the disease transformed into ALL and the patient expired. Thus, an ETV6/ABL1 fusion positive MPN has the potential to transform very rapidly into ALL. Elsevier 2016-10-14 /pmc/articles/PMC5078675/ /pubmed/27812500 http://dx.doi.org/10.1016/j.lrr.2016.09.002 Text en © 2016 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Article Kakadia, Purvi M. Schmidmaier, Ralf Völkl, Andreas Schneider, Irene Huk, Natalia Schneider, Stephanie Panzner, Gerda Neidel, Ulrike Fritz, Barbara Spiekermann, Karsten Bohlander, Stefan K. An ETV6-ABL1 fusion in a patient with chronic myeloproliferative neoplasm: Initial response to Imatinib followed by rapid transformation into ALL |
title | An ETV6-ABL1 fusion in a patient with chronic myeloproliferative neoplasm: Initial response to Imatinib followed by rapid transformation into ALL |
title_full | An ETV6-ABL1 fusion in a patient with chronic myeloproliferative neoplasm: Initial response to Imatinib followed by rapid transformation into ALL |
title_fullStr | An ETV6-ABL1 fusion in a patient with chronic myeloproliferative neoplasm: Initial response to Imatinib followed by rapid transformation into ALL |
title_full_unstemmed | An ETV6-ABL1 fusion in a patient with chronic myeloproliferative neoplasm: Initial response to Imatinib followed by rapid transformation into ALL |
title_short | An ETV6-ABL1 fusion in a patient with chronic myeloproliferative neoplasm: Initial response to Imatinib followed by rapid transformation into ALL |
title_sort | etv6-abl1 fusion in a patient with chronic myeloproliferative neoplasm: initial response to imatinib followed by rapid transformation into all |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5078675/ https://www.ncbi.nlm.nih.gov/pubmed/27812500 http://dx.doi.org/10.1016/j.lrr.2016.09.002 |
work_keys_str_mv | AT kakadiapurvim anetv6abl1fusioninapatientwithchronicmyeloproliferativeneoplasminitialresponsetoimatinibfollowedbyrapidtransformationintoall AT schmidmaierralf anetv6abl1fusioninapatientwithchronicmyeloproliferativeneoplasminitialresponsetoimatinibfollowedbyrapidtransformationintoall AT volklandreas anetv6abl1fusioninapatientwithchronicmyeloproliferativeneoplasminitialresponsetoimatinibfollowedbyrapidtransformationintoall AT schneiderirene anetv6abl1fusioninapatientwithchronicmyeloproliferativeneoplasminitialresponsetoimatinibfollowedbyrapidtransformationintoall AT huknatalia anetv6abl1fusioninapatientwithchronicmyeloproliferativeneoplasminitialresponsetoimatinibfollowedbyrapidtransformationintoall AT schneiderstephanie anetv6abl1fusioninapatientwithchronicmyeloproliferativeneoplasminitialresponsetoimatinibfollowedbyrapidtransformationintoall AT panznergerda anetv6abl1fusioninapatientwithchronicmyeloproliferativeneoplasminitialresponsetoimatinibfollowedbyrapidtransformationintoall AT neidelulrike anetv6abl1fusioninapatientwithchronicmyeloproliferativeneoplasminitialresponsetoimatinibfollowedbyrapidtransformationintoall AT fritzbarbara anetv6abl1fusioninapatientwithchronicmyeloproliferativeneoplasminitialresponsetoimatinibfollowedbyrapidtransformationintoall AT spiekermannkarsten anetv6abl1fusioninapatientwithchronicmyeloproliferativeneoplasminitialresponsetoimatinibfollowedbyrapidtransformationintoall AT bohlanderstefank anetv6abl1fusioninapatientwithchronicmyeloproliferativeneoplasminitialresponsetoimatinibfollowedbyrapidtransformationintoall AT kakadiapurvim etv6abl1fusioninapatientwithchronicmyeloproliferativeneoplasminitialresponsetoimatinibfollowedbyrapidtransformationintoall AT schmidmaierralf etv6abl1fusioninapatientwithchronicmyeloproliferativeneoplasminitialresponsetoimatinibfollowedbyrapidtransformationintoall AT volklandreas etv6abl1fusioninapatientwithchronicmyeloproliferativeneoplasminitialresponsetoimatinibfollowedbyrapidtransformationintoall AT schneiderirene etv6abl1fusioninapatientwithchronicmyeloproliferativeneoplasminitialresponsetoimatinibfollowedbyrapidtransformationintoall AT huknatalia etv6abl1fusioninapatientwithchronicmyeloproliferativeneoplasminitialresponsetoimatinibfollowedbyrapidtransformationintoall AT schneiderstephanie etv6abl1fusioninapatientwithchronicmyeloproliferativeneoplasminitialresponsetoimatinibfollowedbyrapidtransformationintoall AT panznergerda etv6abl1fusioninapatientwithchronicmyeloproliferativeneoplasminitialresponsetoimatinibfollowedbyrapidtransformationintoall AT neidelulrike etv6abl1fusioninapatientwithchronicmyeloproliferativeneoplasminitialresponsetoimatinibfollowedbyrapidtransformationintoall AT fritzbarbara etv6abl1fusioninapatientwithchronicmyeloproliferativeneoplasminitialresponsetoimatinibfollowedbyrapidtransformationintoall AT spiekermannkarsten etv6abl1fusioninapatientwithchronicmyeloproliferativeneoplasminitialresponsetoimatinibfollowedbyrapidtransformationintoall AT bohlanderstefank etv6abl1fusioninapatientwithchronicmyeloproliferativeneoplasminitialresponsetoimatinibfollowedbyrapidtransformationintoall |